Advances in Immunotherapy and Precision Targeted Cancer Therapies
Session Overview
The advent of immunotherapy and precision targeted agents has fundamentally reshaped the oncology landscape, moving treatment from a histology-based to a mechanism-driven paradigm. This revolution, powered by immune checkpoint blockade, engineered cellular therapies, and antibody-based platforms, has delivered durable responses in previously untreatable cancers. This session brings together translational scientists, clinical trialists, and immunologists to critically examine the current frontiers, persistent challenges, and next-generation strategies in harnessing the immune system and targeting molecular pathways against cancer.
Why This Session Matters Now
Immunotherapy has transitioned from a novel approach to a backbone of treatment for numerous malignancies, yet primary and acquired resistance limit its benefit to a subset of patients. The field is now defined by the urgent quest to understand resistance mechanisms, identify predictive biomarkers, and rationally combine modalities to overcome immunosuppressive tumors. Simultaneously, the clinical integration of complex cellular products (CAR-T, TCR) and sophisticated antibody constructs demands innovations in manufacturing, toxicity management, and access. This session addresses the pivotal shift from demonstrating efficacy to optimizing implementation and personalizing immunotherapeutic strategies.
Key Scientific and Clinical Themes
Immune Checkpoint Inhibitors and Novel Immune Targets
Critical appraisal of the expanding universe of checkpoint targets beyond PD-1/PD-L1 and CTLA-4, the biology of the tumor immune microenvironment, and strategies to convert “cold” tumors to “hot” ones.
CAR-T, TCR, and Engineered Cell-Based Therapies
Examination of advances in the design, manufacturing, and clinical application of adoptive cell therapies for solid and hematologic malignancies, including managing unique toxicities (CRS, ICANS) and overcoming antigen escape.
Cancer Vaccines and Oncolytic Viral Therapies
Analysis of next-generation therapeutic vaccine platforms (mRNA, neoantigen) and engineered oncolytic viruses, focusing on their role as monotherapy and in combination with checkpoint inhibition to stimulate de novo anti-tumor immunity.
Antibody–Drug Conjugates and Bispecific Antibodies
Discussion of the pharmacology and clinical development of ADCs and bispecific T-cell engagers (BiTEs), emphasizing target selection, payload innovation, and managing on-target/off-tumor toxicities.
Resistance Mechanisms to Immunotherapy and Targeted Agents
Deep dive into the cellular, metabolic, and genomic mechanisms underlying treatment failure, exploring strategies to target compensatory pathways, the immunosuppressive niche, and tumor cell plasticity.
Combination Immunotherapy and Precision Treatment Strategies
Rationale and trial design for combining immunotherapies with targeted agents, chemotherapy, radiotherapy, and local ablative therapies, guided by biomarker-driven patient selection.
Nature of Research in This Field
Research in this domain is characterized by an unparalleled pace of translation, requiring close collaboration between basic immunology and clinical oncology. The literature is dominated by a continuous cycle of high-impact clinical trial results followed by intensive mechanistic dissection and synthesis in reviews. A significant portion of effort is dedicated to biomarker discovery and the development of preclinical models that faithfully recapitulate the human immune-tumor interaction. The field is increasingly focused on real-world evidence and health outcomes research as these therapies become standard of care.
Who Should Attend
This session is designed for:
- Medical oncologists, hematologists, and translational researchers
- Cancer immunologists, cellular therapists, and bioengineers
- Clinical trial specialists and drug development scientists
- Pathologists and molecular diagnosticians involved in biomarker development
- Fellows and trainees seeking a comprehensive state-of-the-art overview
Session Perspective
Immunotherapy has proven the principle that a patient’s immune system can be a powerful ally against cancer. The current challenge is to make this alliance effective for every patient. This session provides a platform to move beyond initial success stories to tackle the hard problems of resistance, toxicity, and accessibility. By connecting deep mechanistic insight with pragmatic clinical trial design, the discussion aims to chart a course toward more precise, potent, and personalized immunotherapeutic approaches that fulfill the paradigm’s initial promise.
If your research aligns with this session, we invite you to submit an abstract for consideration.
